AMPH · Amphastar Pharmaceuticals, Inc.

Summary

On March 12, 2026, Amphastar Pharmaceuticals, Inc.’s Board of Directors authorized a $50 million increase to the Company’s share buyback program, expected to continue for an indefinite period. The primary goal is to offset dilution created by the Company’s equity compensation programs, with purchases through open market, Rule 10b5-1 plans, or other means compliant with SEC requirements.

Key takeaways

• Board authorized $50 million increase to share buyback program on March 12, 2026
• Program to continue indefinitely
• Goal: offset dilution from equity compensation programs
• Purchases via open market, private block transactions, Rule 10b5-1 plans, or other means